Interleukin-5 Induces CD34(+) Eosinophil Progenitor Mobilization and Eosinophil CCR3 Expression in Asthma
Overview
Affiliations
Asthma is characterized by the accumulation of activated T cells and eosinophils within the airway. Eosinophils derive from CD34(+) bone marrow progenitor cells under the influence of hematopoietic growth factors, subsequently migrating to the airways under the cooperative influence of interleukin (IL)-5 and chemokines, including eotaxin. We compared the relative effects of systemic versus local IL-5 on progenitor-cell mobilization and mature eosinophil phenotype by using flow cytometry, following the administration of intravenous (2 microg) or inhaled (15 microg) IL-5 to nine patients with mild asthma. Intravenous IL-5 induced a rapid reduction in circulating eosinophil counts followed by prolonged blood eosinophilia. Both intravenous (p < 0.002) and inhaled (p < 0.05) IL-5 significantly increased CD34(+)/CD45(+) lymphoblastoid eosinophil progenitors. Intravenous IL-5 increased mature eosinophil CCR3 expression from a baseline mean fluorescence intensity (MFI) of 658 +/- 51.7 to 995 +/- 93.2 at 24 h (p < 0.05), but had no effect on interleukin-5 receptor subunit alpha or CD11b expression. Lymphocyte CCR3 MFI was increased by intravenous IL-5 from 38.5 +/- 13.6 at baseline to 73.6 +/- 14.3 at 24 h (p < 0.05). Systemic IL-5 increased circulating eosinophil progenitors, suggesting a key role for systemic IL-5 in eosinophil mobilization. Further, IL-5 causes terminal maturation of the eosinophil by increasing CCR3 expression, potentially affecting CCR3-dependent chemotaxis by eosinophils and lymphocytes.
Pavord I, Chan R, Brown N, Howarth P, Gilson M, Price R Ann Med. 2024; 56(1):2417184.
PMID: 39465531 PMC: 11520089. DOI: 10.1080/07853890.2024.2417184.
Regulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets.
Hansi R, Ranjbar M, Whetstone C, Gauvreau G Biomedicines. 2024; 12(10).
PMID: 39457624 PMC: 11505104. DOI: 10.3390/biomedicines12102312.
Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases.
Antosz K, Batko J, Blazejewska M, Gawor A, Sleziak J, Gomulka K Biomedicines. 2024; 12(7).
PMID: 39062104 PMC: 11275030. DOI: 10.3390/biomedicines12071531.
Chen R, Wei L, Dai Y, Wang Z, Yang D, Jin M ERJ Open Res. 2024; 10(3).
PMID: 38770009 PMC: 11103715. DOI: 10.1183/23120541.00750-2023.
Hwee J, Harper L, Fu Q, Nirantharakumar K, Mu G, Jakes R ERJ Open Res. 2024; 10(3).
PMID: 38746859 PMC: 11089387. DOI: 10.1183/23120541.00430-2023.